Published in J Neurosurg on August 01, 2010
Surgical management of primary spinal hemangiopericytomas: an institutional case series and review of the literature. Eur Spine J (2013) 1.01
Clinical analysis of intracranial hemangiopericytoma. J Korean Neurosurg Soc (2013) 0.90
CyberKnife stereotactic radiosurgery for recurrent, metastatic, and residual hemangiopericytomas. J Hematol Oncol (2011) 0.84
Meningeal Hemangiopericytoma with Intracranial Metastases in an HIV-Positive Male: Case Report and Review of the Literature. Case Rep Oncol (2012) 0.79
Intracranial meningeal hemangiopericytoma: Recurrences at the initial and distant intracranial sites and extraneural metastases to multiple organs. Mol Clin Oncol (2015) 0.79
Rare primary central nervous system tumors. Rare Tumors (2014) 0.77
Multidisciplinary Approach to Hepatic Metastases of Intracranial Hemangiopericytoma: A Case Report and Review of the Literature. Case Rep Oncol Med (2015) 0.77
Treatment Strategy of Intracranial Hemangiopericytoma. Brain Tumor Res Treat (2015) 0.75
What lies beneath. BMJ Case Rep (2013) 0.75
[Complete radiological response of meningeal hemangiopericytoma after adjuvant radiotherapy to incomplete excision]. Pan Afr Med J (2014) 0.75
Multiple dural-based hemangiopericytomas. Proc (Bayl Univ Med Cent) (2016) 0.75
Laparoscopic resection of intra-abdominal metastasis from intracranial hemangiopericytoma. Int J Surg Case Rep (2015) 0.75
Intracranial Hemangiopericytomas: Recurrence, Metastasis, and Radiotherapy. J Neurol Surg B Skull Base (2017) 0.75
Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. J Neurooncol (2017) 0.75
An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg (2011) 6.32
Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature (2004) 5.85
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol (2008) 2.71
Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article. J Neurosurg (2010) 2.42
Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg (2010) 2.19
Modern surgical outcomes following surgery for sphenoid wing meningiomas. J Neurosurg (2013) 2.16
Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology (2009) 2.15
Complications of lumboperitoneal shunts. Neurosurgery (2007) 2.07
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol (2012) 2.04
Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res (2013) 1.86
Factors affecting outcome following treatment of patients with cavernous sinus meningiomas. J Neurosurg (2010) 1.74
Surgical technique of temporary arterial occlusion in the operative management of spinal hemangioblastomas. World Neurosurg (2010) 1.72
Apparatus dependence of normal brain tissue dose in stereotactic radiosurgery for multiple brain metastases. J Neurosurg (2011) 1.71
The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg (2010) 1.67
Posttreatment prognosis of patients with esthesioneuroblastoma. J Neurosurg (2010) 1.67
Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J Neurosurg (2011) 1.67
Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg (2008) 1.66
Cancer and the complement cascade. Mol Cancer Res (2010) 1.64
Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. J Neurosurg (2012) 1.64
Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res (2006) 1.63
The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci (2009) 1.62
Beyond audiofacial morbidity after vestibular schwannoma surgery. J Neurosurg (2009) 1.59
Treatment-related morbidity and the management of pediatric craniopharyngioma: a systematic review. J Neurosurg Pediatr (2012) 1.57
Intratumoral hemorrhage and fibrosis in vestibular schwannoma: a possible mechanism for hearing loss. J Neurosurg (2010) 1.55
Frequency and predictors of complications in neurological surgery: national trends from 2006 to 2011. J Neurosurg (2013) 1.55
Atypia predicting prognosis for intracranial extraventricular neurocytomas. J Neurosurg (2011) 1.54
Extent of resection and the long-term durability of vestibular schwannoma surgery. J Neurosurg (2011) 1.53
Risk factors for the development of serious medical complications after resection of meningiomas. Clinical article. J Neurosurg (2010) 1.53
Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. Cancer Res (2006) 1.52
Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review. J Neurosurg Spine (2013) 1.51
Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma. J Neurosurg (2015) 1.48
Prevalence of previous extracranial malignancies in a series of 1228 patients presenting with meningioma. J Neurosurg (2010) 1.48
A prospective study of hearing preservation in untreated vestibular schwannomas. J Neurosurg (2010) 1.46
What clinical factors predict the incidence of deep venous thrombosis and pulmonary embolism in neurosurgical patients? J Neurosurg (2014) 1.44
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro Oncol (2009) 1.43
Physics strategies for sparing neural stem cells during whole-brain radiation treatments. Med Phys (2011) 1.43
Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg (2010) 1.38
From the notch to a glioma grading system: the neurological contributions of James Watson Kernohan. Neurosurg Focus (2014) 1.38
Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol (2012) 1.38
Intracranial hemangiopericytoma: clinical experience and treatment considerations in a modern series of 40 adult patients. Cancer (2011) 1.35
Honokiol-mediated inhibition of PI3K/mTOR pathway: a potential strategy to overcome immunoresistance in glioma, breast, and prostate carcinoma without impacting T cell function. J Immunother (2009) 1.33
The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. Neurosurg Focus (2011) 1.33
Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J Neurosurg (2009) 1.32
Relationship of glioblastoma multiforme to the subventricular zone is associated with survival. Neuro Oncol (2012) 1.29
Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology (2010) 1.28
CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci (2010) 1.26
Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury. J Neurosurg (2005) 1.25
Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity. J Neurooncol (2009) 1.25
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol (2013) 1.25
Changes in transcranial motor evoked potentials during intramedullary spinal cord tumor resection correlate with postoperative motor function. Neurosurgery (2005) 1.24
Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clin Cancer Res (2012) 1.15
The complement cascade as a mediator of tissue growth and regeneration. Inflamm Res (2010) 1.14
Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment. Neurosurgery (2012) 1.13
A systematic review of intracranial chondrosarcoma and survival. J Clin Neurosci (2009) 1.13
A comprehensive analysis of hearing preservation after radiosurgery for vestibular schwannoma. J Neurosurg (2010) 1.11
Medicinal herb use among asthmatic patients attending a specialty care facility in Trinidad. BMC Complement Altern Med (2005) 1.09
Neurologic assessment of somatosensory dysfunction following an experimental rodent model of cerebral ischemia. Nat Protoc (2007) 1.09
Current management of middle cerebral artery aneurysms: surgical results with a "clip first" policy. Neurosurgery (2013) 1.07
A meta-analysis of tumor control rates and treatment-related morbidity for patients with glomus jugulare tumors. J Neurosurg (2010) 1.07
Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. J Neurooncol (2009) 1.06
A meta-analysis of predictors of seizure freedom in the surgical management of focal cortical dysplasia. J Neurosurg (2012) 1.06
Cranial chondrosarcoma and recurrence. Skull Base (2010) 1.06
Craniopharyngioma: a comparison of tumor control with various treatment strategies. Neurosurg Focus (2010) 1.05